{"slug":"hormone-receptor","tag":"hormone-receptor","variants":["hormone-receptor"],"description":"No description yet","count":3,"kinds":{"biomarker":3},"related":[{"slug":"biomarker","tag":"biomarker","shared":3},{"slug":"resistance","tag":"resistance","shared":1}],"records":[{"id":"er-status","kind":"biomarker","name":"ER status (oestrogen receptor by IHC)","route":"/biomarkers/er-status/","tldr":"ER status is whether the tumour's cells carry the oestrogen receptor, read by staining nuclei. One percent or more of stained nuclei is positive and means hormone-blocking treatment can work; 1 to 10 percent is 'low positive' and behaves more like negative."},{"id":"pr-status","kind":"biomarker","name":"PR status (progesterone receptor by IHC)","route":"/biomarkers/pr-status/","tldr":"PR status is read the same way as ER: 1 percent or more of nuclei staining is positive. It is measured alongside ER, adds to prognosis, and a tumour positive for either receptor counts as hormone-receptor-positive."},{"id":"esr1-mutation-ctdna","kind":"biomarker","name":"ESR1 mutation (ligand-binding domain, usually in ctDNA)","route":"/biomarkers/esr1-mutation-ctdna/","tldr":"ESR1 mutations arise in the oestrogen receptor's ligand-binding domain after aromatase inhibitor treatment, letting the receptor work without oestrogen. They are usually found in a blood test and select the oral SERDs elacestrant and imlunestrant."}]}